The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice

Liver International

Volumn 30, Issue 4, 2010, Pages 603-610

  de Fraia Pinto, Livia ^a   Compri, Cecília Melleti ^a   Fornari, João Victor ^a   Bartchewsky, Waldemar ^a   Cintra, Dennys Eduardo ^b   Trevisan, Miriam ^c   de Oliveira Carvalho, Patrícia ^a   Ribeiro, Marcelo Lima ^a   Velloso, Licio A ^b   Saad, Mario J ^b   Pedrazzoli, José ^a   Gambero, Alessandra ^a  

^a Universidade Sao Francisco Centro de Ciencias Biologicas e da Saude   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NONE

Author keywords

IL 6; INOS; Insulin receptor substrate; Non alcoholic fatty liver disease; SOCS; TNF

Indexed keywords

CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; SUPPRESSOR OF CYTOKINE SIGNALING 3; THALIDOMIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HISTOLOGY; INSULIN TOLERANCE TEST; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; STEATOSIS;

ANIMALS; BIOPSY, NEEDLE; BLOOD GLUCOSE; DIET; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; LIVER; LIVER FUNCTION TESTS; MALE; MICE; NITRIC OXIDE SYNTHASE; OBESITY; PROBABILITY; RANDOM ALLOCATION; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950617221     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02200.x     Document Type: Article

References (30)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-7.
2. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19:525-46.
3. Kamei N, Tobe K, Suzuki R. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281:26602-14.
4. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-52.
5. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007, 47:142-56.
6. Tomita K, Tamiya G, Ando S. Tumor necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415-24.
7. Hotamisligil GS, Peraldi P, Budavari A. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-8.
8. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277:42394-8.
9. Bonora E, Manicardi V, Zavaroni I, Coscelli C, Butturini U. Relationships between insulin secretion, insulin metabolism and insulin resistance in mild glucose intolerance. Diabetes Metab 1987, 13:116-21.
10. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982, 28:2077-80.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-8.
12. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002, 22:425-37.
13. Shannon EJ, Morales MJ, Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 1997, 35:203-12.
14. Ye Q, Chen B, Tong Z. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006, 28:824-31.
15. Muriel P, Fernández-Martínez E, Pérez-Alvarez V. Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat. Eur J Gastroenterol Hepatol 2003, 15:951-7.
16. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci 2006, 13:403-18.
17. Rupnick MA, Panigrahy D, Zhang CY. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002, 99:10730-5.
18. Cintra DE, Pauli JR, Araújo EP. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol 2008, 48:628-37.
19. Day CP. NASH-related liver failure: one hit too many? Am J Gastroenterol 2002, 97:1872-4.
20. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2005, 34:45-61.
21. Araújo EP, De Souza CT, Ueno M. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007, 148:5991-7.
22. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007, 194:539-50.
23. Iqbal N, Zayed M, Boden G. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care 2000, 23:1172-6.
24. Efstathiou E, Troncoso P, Wen S. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007, 13:1224-31.
25. Shannon E, Noveck R, Sandoval F, Kamath B, Kearney M. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Transl Res 2007, 150:275-80.
26. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998, 244:178-82.
27. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 2005, 33:185-92.
28. Fujimoto M, Shimizu N, Kunii K. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 2005, 54:1340-8.
29. Carvalho-Filho MA, Ueno M, Carvalheira JB, Velloso LA, Saad MJ. Targeted disruption of iNOS prevents LPS-induced S-nitrosation of IRbeta/IRS-1 and Akt and insulin resistance in muscle of mice. Am J Physiol Endocrinol Metabol 2006, 291:E476-82.
30. Rodrigues GB, Passos GF, Di Giunta G. Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res 2007, 84:553-60.